In 2010, using a biochemical oncosimulator, Wan et al. (304) investigated the binding affinities for AEE788 and Gefitinib tyrosine kinase inhibitor against mutated epidermal growth factor receptor (EGFR) for NSCLC treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.